Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4481-4485

  Lepetic, A ^a   Biscayart, C ^a   Seigelchifer, M ^b   Arduino, R ^c   Stamboulian, D ^a  

^a Centro de Estudios Infectologicos   (Argentina)

^b PC Gen SA   (Argentina)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Hansenula polymorpha; Hepatitis B vaccine; Immunogenicity; Long term seroprotection

Indexed keywords

AGB; HEMAGGLUTININ; HEPATITIS B VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HANSENULA POLYMORPHA; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION; VOLUNTEER;

EID: 0347448149     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00306-2     Document Type: Article

References (25)

1. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 1999. p. 158-82.
2. Ambrosch F., Frisch-Niggemeyer W., Kremsner P.et al. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad. Med. J. 63(Suppl. 2):1987;129-135.
3. Assad S., Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 18:2000;57-67.
4. Scheiermann N., Gesemann M., Maurer C., Just M., Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine. 8:1990;S44-S56.
5. Just M., Berger R.M., Scheiermann N. Persistence of antibodies following vaccination with a yeast derived recombinant hepatitis B vaccine. Vaccine. 6:1988;401-402.
6. Van Herck K., Van Damme P., Thoelen S., Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine. 16:1998;1933-1935.
7. Gellissen G., Janowicz Z.A., Weydemann U., Melber K., Strasser A.W.M., Hollenberg C.P. High-level expression of foreign genes in Hansenula polymorpha. Biotech. Adv. 10:1992;179-189.
8. Gellissen G., Melber K., Janowicz Z.A.et al. Heterologous protein productions in yeast. Antonie Van Leeuwenhoek (Int. J. Gen. Mol. Microbiol.). 62:1992;79-93.
9. Gellissen G., Weydemann U., Strasser A.W.M., Piontek M., Janowicz Z.A., Hollenberg C.P. Progress in developing methylotrophic yeasts as expression systems. Tibtech. 10:1992;413-417.
10. Lepetic A, Seigelchifer M, Arduino RC, et al. A novel recombinant hepatitis B vaccine produced by a high-level expression Hansenula polymorpha yeast system. Presented at the IDSA 34th Annual Meeting, New Orleans; 1996.
11. Gleeson M.A., Sudbery P.E. The methylotropic yeasts. Yeast. 4:1988;1-15.
12. Roggenkamp R.O., Janowicz Z.A., Stanikowski B., Hollemberg C.P. Biosyntesis and regulation of peroxysomal methanol oxidase from the methylotropic yeast Hansenula polymorpha. Mol. Gen. Genet. 194:1984;489-493.
13. Cregg JM, Madden PA. Development of yeast transformation systems and construction of methanol-utilizing-defective mutants of Pichia pastoris by gene disruption. In: Stewart GG, Russell I, Klein RD, Hiebsch RR, editors. Biological research on industrial yeast, vol. II. Boca Raton: CRC Press; 1987. p. 1-18.
14. Gellisen G., Strasser A.W.M., Melber K.et al. Die methylotrophe Hefe Hansenula polymorpha als expressionssystem für heterologe proteine. Bioengineering. 5:1990;20-26.
15. Buckholz R.G., Gleeson M.A. Yeast systems for the commercial production of heterologous proteins. Biotechnology. 9:1991;1067-1072.
16. Shen S.H., Bastien L., Nguyen T., Fung M., Slilaty S.N. Synthesis and secretion of hepatitis B middle surface antigen by the methylotropic yeast Hansenula polymorpha. Gene. 84:1989;304-309.
17. Janowicz Z.A., Melber K., Merckelbach A., Jacobs E., Harford N., Comberbach M., Hollenberg C.P. Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotropic yeast, Hansenula polymorpha. Yeast. 7:1991;431-443.
18. World Health Organization. Weekly Epidemiol Rec 1997;72:149-56.
19. Morgan DR, editor. A code of practices for implementation of the UK hepatitis B immunisation guidelines for the protection of patients and staff. London: BMA; 1995 [edited for the British Medical Association Board of Sciences and Education].
20. Jilg W., Schmidt M., Deinhart F., Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet. ii:1985;458.
21. Stevens C.E., Toy P.T., Taylor P.E.et al. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long term protection. Pediatrics. 90(Suppl.):1992;170-173.
22. Goh K.T., Oon C.J., Heng B.H., Lim G.K. Long-term immunogenicity and efficacy of a reduced dose of plama-based hepatitis B vaccine in young adults. Bull. World Health Organ. 73:1995;523-527.
23. Courouce AM, Loplanche A, Benhamou E, Jungers P. Long-term efficacy of hepatitis B vaccination in healthy adults. In: Zuckermann AJ, editor. Viral hepatitis and liver disease. New York: Liss; 1988. p. 1002-5.
24. Albareda M, Muchinik G, Maulen S, et al. Study of safety, tolerance and immunogenicity of a new recombinant vaccine anti-hepatitis B. Presented at the 9th International Congress of Infectious Diseases, Buenos Aires; 2000.
25. Sarubbi MA, Rocha M, Seigelchifer M, et al. Evaluation of a novel hepatitis B vaccine administered to newborns and adolescent mothers: preliminary information. Presented at the 9th International Congress of Infectious Diseases, Buenos Aires; 2000.